FDA Draft Guidance on RUO/IUO Products Proposes Tough Changes for Industry Players
June 08, 2011
FDA Draft Guidance on RUO/IUO Products Proposes Tough Changes for Industry Players
Given that RUO/IUO products are being marketed and used by life science players in numerous ways, the FDA's proposed restrictions will not be an easy task for industry to implement or for the agency to enforce.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Q&A: Lawyer Jeff Gibbs Discusses Implications of Veterinary Drug Case on FDA's LDT, RUO Guidances
January 18, 2012 / Pharmacogenomics Reporter - FDA Keeping All Ideas in Play in Soliciting Public Comments on LDT Regulation
July 21, 2010 / Pharmacogenomics Reporter - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter - At Dx Conference, FDA's Gutierrez Sheds Further Light on Plans for Risk-Based LDT Regulation
September 7, 2011 / Pharmacogenomics Reporter - FDA Mulls Options for Regulating Next-Gen Sequencing Platforms in Clinical Diagnostics
June 29, 2011 / Clinical Sequencing News